Veracyte Insider Share Sales
Veracyte CEO Marc Stapley Sells $6.9M in Shares Amid Strong Earnings, Tax Obligations
Veracyte insiders including CFO Rebecca Chambers, EVP Annie McGuire, and executives such as CEO Marc Stapley and John Leite sold multiple blocks of company shares on June 4 under pre-arranged Rule 10b5-1 plans, with the transactions largely tied to equity-vesting tax obligations (and, for Stapley, also to stock option exercise). The sales were executed at prices around the high-$49 to low-$50 range and resulted in meaningful reductions in the insiders’ respective holdings. The company’s most recent quarterly report, released May 5, showed stronger-than-expected performance, with EPS of 0.52 versus a 0.34 consensus and revenue of $139.07 million versus $130.36 million, alongside year-over-year revenue growth. Veracyte’s stock was trading near its 52-week high after the earnings update. Analyst views remain mixed, with some firms lowering price targets and others upgrading or reiterating bullish stances.
Key Points
CFO Rebecca Chambers sold 3,561 shares on June 4 at an average price of $49.73 (total $177,088.53) and still owned 173,280 shares afterward—about a 2.01% reduction in her position. The sale was executed under a pre-arranged Rule 10b5-1 plan and was attributed to tax withholding tied to vesting of equity awards.
Insider John Leite sold 13,975 shares on June 4 at an average price of $50.07 (total $699,728.25) and owned 132,305 shares following the transaction—about a 9.55% decrease. The filing described the sale as being under a Rule 10b5-1 plan to cover tax withholding obligations related to equity award vesting.
CEO Marc Stapley’s June 4 sale was reported as 138,051 shares sold at a weighted average price of $50.1234 (total about $6.92 million), with individual sale prices ranging from $50.00 to $50.52. The transaction followed the exercise of an equal number of fully vested stock options at $36.60 per share (about $5.05 million in option acquisition value), and the Rule 10b5-1 trading plan was adopted on November 24, 2025.
Stapley also had a separate June 2 disposal of 9,012 shares at $47.80 per share (about $430,773 total) to satisfy tax withholding obligations connected to the vesting of restricted stock units; this was described as non-discretionary and not a separate voluntary sale decision.
In the earnings context, Veracyte reported profitability metrics alongside the EPS/revenue beat: net margin of 16.25% and return on equity of 9.07%, and revenue up 21.5% year over year. Separately, Wolfe Research upgraded Veracyte to a “strong-buy.”
Sentiment
Mostly PositivePublishers
11
Articles
7
Reach
18
